Jaqueline Isquierdo
Optometrist · Santa Fe, NMNPI 1356125173
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 34.1% of the total. 2025 is the largest year on record at $861, 5.3 times the $163 reported in 2023.
Across 35 payments — averaging $43.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$515
- Dompe US, Inc.$248
- Alcon$201
- AbbVie$167
- Sun Pharmaceutical Industries Inc.$139
- Tarsus Pharmaceuticals, Inc.$121
- plus $119 from 3 others
What the payments were for
- Food & beverage$1,510100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 15 | $515 |
| Dompe US, Inc. | 3 | $248 |
| Alcon | 3 | $201 |
| AbbVie | 3 | $167 |
| Sun Pharmaceutical Industries Inc. | 5 | $139 |
| Tarsus Pharmaceuticals, Inc. | 1 | $121 |
| Coopervision Inc. | 2 | $50 |
| Johnson & Johnson Vision Care, Inc. | 2 | $40 |
| Harrow Eye, LLC | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,510 in reported general payments places this provider in the 80th percentile of 228 optometrist providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $166 |
| Latanoprost | 16 | $90 |
Paid to pharmacies, not to this prescriber.
Other optometrist in Santa Fe
- David ViseSanta Fe$8K
- Dwight ThibodeauxSanta Fe$5K
- Paul TachauSanta Fe$4K
- Shinichi HamashigeSanta Fe$3K
- Micayla Fisher-IvesSanta Fe$1K
- Vanlin BotwinSanta Fe$946
- Keith BarkerClovis$52K
- Elysia IsonShiprock$37K
- David BabingtonAlbuquerque$8K
- Nicolette EstradaAlbuquerque$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.